Global Overactive Bladder Drug Market Growth 2022-2028

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Overactive Bladder Drug Annual Sales 2017-2028

2.1.2 World Current & Future Analysis for Overactive Bladder Drug by Geographic Region, 2017, 2022 & 2028

2.1.3 World Current & Future Analysis for Overactive Bladder Drug by Country/Region, 2017, 2022 & 2028

2.2 Overactive Bladder Drug Segment by Type

2.2.1 Anticholinergics

2.2.2 Solifenacin

2.2.3 Oxybutynin

2.2.4 Darifenacin

2.2.5 Fesoterodine

2.2.6 Tolterodine

2.2.7 Trospium

2.2.8 Others

2.3 Overactive Bladder Drug Sales by Type

2.3.1 Global Overactive Bladder Drug Sales Market Share by Type (2017-2022)

2.3.2 Global Overactive Bladder Drug Revenue and Market Share by Type (2017-2022)

2.3.3 Global Overactive Bladder Drug Sale Price by Type (2017-2022)

2.4 Overactive Bladder Drug Segment by Application

2.4.1 Idiopathic Bladder Overactivity

2.4.2 Neurogenic Bladder Overactivity

2.5 Overactive Bladder Drug Sales by Application

2.5.1 Global Overactive Bladder Drug Sale Market Share by Application (2017-2022)

2.5.2 Global Overactive Bladder Drug Revenue and Market Share by Application (2017-2022)

2.5.3 Global Overactive Bladder Drug Sale Price by Application (2017-2022)

3 Global Overactive Bladder Drug by Company

3.1 Global Overactive Bladder Drug Breakdown Data by Company

3.1.1 Global Overactive Bladder Drug Annual Sales by Company (2020-2022)

3.1.2 Global Overactive Bladder Drug Sales Market Share by Company (2020-2022)

3.2 Global Overactive Bladder Drug Annual Revenue by Company (2020-2022)

3.2.1 Global Overactive Bladder Drug Revenue by Company (2020-2022)

3.2.2 Global Overactive Bladder Drug Revenue Market Share by Company (2020-2022)

3.3 Global Overactive Bladder Drug Sale Price by Company

3.4 Key Manufacturers Overactive Bladder Drug Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Overactive Bladder Drug Product Location Distribution

3.4.2 Players Overactive Bladder Drug Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Overactive Bladder Drug by Geographic Region

4.1 World Historic Overactive Bladder Drug Market Size by Geographic Region (2017-2022)

4.1.1 Global Overactive Bladder Drug Annual Sales by Geographic Region (2017-2022)

4.1.2 Global Overactive Bladder Drug Annual Revenue by Geographic Region

4.2 World Historic Overactive Bladder Drug Market Size by Country/Region (2017-2022)

4.2.1 Global Overactive Bladder Drug Annual Sales by Country/Region (2017-2022)

4.2.2 Global Overactive Bladder Drug Annual Revenue by Country/Region

4.3 Americas Overactive Bladder Drug Sales Growth

4.4 APAC Overactive Bladder Drug Sales Growth

4.5 Europe Overactive Bladder Drug Sales Growth

4.6 Middle East & Africa Overactive Bladder Drug Sales Growth

5 Americas

5.1 Americas Overactive Bladder Drug Sales by Country

5.1.1 Americas Overactive Bladder Drug Sales by Country (2017-2022)

5.1.2 Americas Overactive Bladder Drug Revenue by Country (2017-2022)

5.2 Americas Overactive Bladder Drug Sales by Type

5.3 Americas Overactive Bladder Drug Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Overactive Bladder Drug Sales by Region

6.1.1 APAC Overactive Bladder Drug Sales by Region (2017-2022)

6.1.2 APAC Overactive Bladder Drug Revenue by Region (2017-2022)

6.2 APAC Overactive Bladder Drug Sales by Type

6.3 APAC Overactive Bladder Drug Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 Europe

7.1 Europe Overactive Bladder Drug by Country

7.1.1 Europe Overactive Bladder Drug Sales by Country (2017-2022)

7.1.2 Europe Overactive Bladder Drug Revenue by Country (2017-2022)

7.2 Europe Overactive Bladder Drug Sales by Type

7.3 Europe Overactive Bladder Drug Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa Overactive Bladder Drug by Country

8.1.1 Middle East & Africa Overactive Bladder Drug Sales by Country (2017-2022)

8.1.2 Middle East & Africa Overactive Bladder Drug Revenue by Country (2017-2022)

8.2 Middle East & Africa Overactive Bladder Drug Sales by Type

8.3 Middle East & Africa Overactive Bladder Drug Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Overactive Bladder Drug

10.3 Manufacturing Process Analysis of Overactive Bladder Drug

10.4 Industry Chain Structure of Overactive Bladder Drug

11 Marketing, Distributors and Customer

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Overactive Bladder Drug Distributors

11.3 Overactive Bladder Drug Customer

12 World Forecast Review for Overactive Bladder Drug by Geographic Region

12.1 Global Overactive Bladder Drug Market Size Forecast by Region

12.1.1 Global Overactive Bladder Drug Forecast by Region (2023-2028)

12.1.2 Global Overactive Bladder Drug Annual Revenue Forecast by Region (2023-2028)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Overactive Bladder Drug Forecast by Type

12.7 Global Overactive Bladder Drug Forecast by Application

13 Key Players Analysis

13.1 Astellas Pharma, Inc. (Japan)

13.1.1 Astellas Pharma, Inc. (Japan) Company Information

13.1.2 Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Product Offered

13.1.3 Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.1.4 Astellas Pharma, Inc. (Japan) Main Business Overview

13.1.5 Astellas Pharma, Inc. (Japan) Latest Developments

13.2 Pfizer, Inc. (US)

13.2.1 Pfizer, Inc. (US) Company Information

13.2.2 Pfizer, Inc. (US) Overactive Bladder Drug Product Offered

13.2.3 Pfizer, Inc. (US) Overactive Bladder Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.2.4 Pfizer, Inc. (US) Main Business Overview

13.2.5 Pfizer, Inc. (US) Latest Developments

13.3 Teva Pharmaceutical Industries Limited (Israel)

13.3.1 Teva Pharmaceutical Industries Limited (Israel) Company Information

13.3.2 Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Product Offered

13.3.3 Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.3.4 Teva Pharmaceutical Industries Limited (Israel) Main Business Overview

13.3.5 Teva Pharmaceutical Industries Limited (Israel) Latest Developments

13.4 Allergan, Plc (Ireland)

13.4.1 Allergan, Plc (Ireland) Company Information

13.4.2 Allergan, Plc (Ireland) Overactive Bladder Drug Product Offered

13.4.3 Allergan, Plc (Ireland) Overactive Bladder Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.4.4 Allergan, Plc (Ireland) Main Business Overview

13.4.5 Allergan, Plc (Ireland) Latest Developments

13.5 Medtronic plc (Ireland)

13.5.1 Medtronic plc (Ireland) Company Information

13.5.2 Medtronic plc (Ireland) Overactive Bladder Drug Product Offered

13.5.3 Medtronic plc (Ireland) Overactive Bladder Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.5.4 Medtronic plc (Ireland) Main Business Overview

13.5.5 Medtronic plc (Ireland) Latest Developments

13.6 Mylan N.V. (US)

13.6.1 Mylan N.V. (US) Company Information

13.6.2 Mylan N.V. (US) Overactive Bladder Drug Product Offered

13.6.3 Mylan N.V. (US) Overactive Bladder Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.6.4 Mylan N.V. (US) Main Business Overview

13.6.5 Mylan N.V. (US) Latest Developments

13.7 Endo International plc (Ireland)

13.7.1 Endo International plc (Ireland) Company Information

13.7.2 Endo International plc (Ireland) Overactive Bladder Drug Product Offered

13.7.3 Endo International plc (Ireland) Overactive Bladder Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.7.4 Endo International plc (Ireland) Main Business Overview

13.7.5 Endo International plc (Ireland) Latest Developments

13.8 Hisamitsu Pharmaceutical Co., Inc. (Japan)

13.8.1 Hisamitsu Pharmaceutical Co., Inc. (Japan) Company Information

13.8.2 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Product Offered

13.8.3 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.8.4 Hisamitsu Pharmaceutical Co., Inc. (Japan) Main Business Overview

13.8.5 Hisamitsu Pharmaceutical Co., Inc. (Japan) Latest Developments

13.9 Sanofi (France)

13.9.1 Sanofi (France) Company Information

13.9.2 Sanofi (France) Overactive Bladder Drug Product Offered

13.9.3 Sanofi (France) Overactive Bladder Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.9.4 Sanofi (France) Main Business Overview

13.9.5 Sanofi (France) Latest Developments

13.10 Apotex, Inc. (Canada)

13.10.1 Apotex, Inc. (Canada) Company Information

13.10.2 Apotex, Inc. (Canada) Overactive Bladder Drug Product Offered

13.10.3 Apotex, Inc. (Canada) Overactive Bladder Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.10.4 Apotex, Inc. (Canada) Main Business Overview

13.10.5 Apotex, Inc. (Canada) Latest Developments

13.11 Cogentix Medical, Inc. (US)

13.11.1 Cogentix Medical, Inc. (US) Company Information

13.11.2 Cogentix Medical, Inc. (US) Overactive Bladder Drug Product Offered

13.11.3 Cogentix Medical, Inc. (US) Overactive Bladder Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.11.4 Cogentix Medical, Inc. (US) Main Business Overview

13.11.5 Cogentix Medical, Inc. (US) Latest Developments

13.12 Aurobindo Pharma Limited (India)

13.12.1 Aurobindo Pharma Limited (India) Company Information

13.12.2 Aurobindo Pharma Limited (India) Overactive Bladder Drug Product Offered

13.12.3 Aurobindo Pharma Limited (India) Overactive Bladder Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.12.4 Aurobindo Pharma Limited (India) Main Business Overview

13.12.5 Aurobindo Pharma Limited (India) Latest Developments

14 Research Findings and Conclusion

Table 1. Overactive Bladder Drug Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)

Table 2. Overactive Bladder Drug Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)

Table 3. Major Players of Anticholinergics

Table 4. Major Players of Solifenacin

Table 5. Major Players of Oxybutynin

Table 6. Major Players of Darifenacin

Table 7. Major Players of Fesoterodine

Table 8. Major Players of Tolterodine

Table 9. Major Players of Trospium

Table 10. Major Players of Others

Table 11. Global Overactive Bladder Drug Sales by Type (2017-2022) & (K Units)

Table 12. Global Overactive Bladder Drug Sales Market Share by Type (2017-2022)

Table 13. Global Overactive Bladder Drug Revenue by Type (2017-2022) & ($ million)

Table 14. Global Overactive Bladder Drug Revenue Market Share by Type (2017-2022)

Table 15. Global Overactive Bladder Drug Sale Price by Type (2017-2022) & (USD/Unit)

Table 16. Global Overactive Bladder Drug Sales by Application (2017-2022) & (K Units)

Table 17. Global Overactive Bladder Drug Sales Market Share by Application (2017-2022)

Table 18. Global Overactive Bladder Drug Revenue by Application (2017-2022)

Table 19. Global Overactive Bladder Drug Revenue Market Share by Application (2017-2022)

Table 20. Global Overactive Bladder Drug Sale Price by Application (2017-2022) & (USD/Unit)

Table 21. Global Overactive Bladder Drug Sales by Company (2020-2022) & (K Units)

Table 22. Global Overactive Bladder Drug Sales Market Share by Company (2020-2022)

Table 23. Global Overactive Bladder Drug Revenue by Company (2020-2022) ($ Millions)

Table 24. Global Overactive Bladder Drug Revenue Market Share by Company (2020-2022)

Table 25. Global Overactive Bladder Drug Sale Price by Company (2020-2022) & (USD/Unit)

Table 26. Key Manufacturers Overactive Bladder Drug Producing Area Distribution and Sales Area

Table 27. Players Overactive Bladder Drug Products Offered

Table 28. Overactive Bladder Drug Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 29. New Products and Potential Entrants

Table 30. Mergers & Acquisitions, Expansion

Table 31. Global Overactive Bladder Drug Sales by Geographic Region (2017-2022) & (K Units)

Table 32. Global Overactive Bladder Drug Sales Market Share Geographic Region (2017-2022)

Table 33. Global Overactive Bladder Drug Revenue by Geographic Region (2017-2022) & ($ millions)

Table 34. Global Overactive Bladder Drug Revenue Market Share by Geographic Region (2017-2022)

Table 35. Global Overactive Bladder Drug Sales by Country/Region (2017-2022) & (K Units)

Table 36. Global Overactive Bladder Drug Sales Market Share by Country/Region (2017-2022)

Table 37. Global Overactive Bladder Drug Revenue by Country/Region (2017-2022) & ($ millions)

Table 38. Global Overactive Bladder Drug Revenue Market Share by Country/Region (2017-2022)

Table 39. Americas Overactive Bladder Drug Sales by Country (2017-2022) & (K Units)

Table 40. Americas Overactive Bladder Drug Sales Market Share by Country (2017-2022)

Table 41. Americas Overactive Bladder Drug Revenue by Country (2017-2022) & ($ Millions)

Table 42. Americas Overactive Bladder Drug Revenue Market Share by Country (2017-2022)

Table 43. Americas Overactive Bladder Drug Sales by Type (2017-2022) & (K Units)

Table 44. Americas Overactive Bladder Drug Sales Market Share by Type (2017-2022)

Table 45. Americas Overactive Bladder Drug Sales by Application (2017-2022) & (K Units)

Table 46. Americas Overactive Bladder Drug Sales Market Share by Application (2017-2022)

Table 47. APAC Overactive Bladder Drug Sales by Region (2017-2022) & (K Units)

Table 48. APAC Overactive Bladder Drug Sales Market Share by Region (2017-2022)

Table 49. APAC Overactive Bladder Drug Revenue by Region (2017-2022) & ($ Millions)

Table 50. APAC Overactive Bladder Drug Revenue Market Share by Region (2017-2022)

Table 51. APAC Overactive Bladder Drug Sales by Type (2017-2022) & (K Units)

Table 52. APAC Overactive Bladder Drug Sales Market Share by Type (2017-2022)

Table 53. APAC Overactive Bladder Drug Sales by Application (2017-2022) & (K Units)

Table 54. APAC Overactive Bladder Drug Sales Market Share by Application (2017-2022)

Table 55. Europe Overactive Bladder Drug Sales by Country (2017-2022) & (K Units)

Table 56. Europe Overactive Bladder Drug Sales Market Share by Country (2017-2022)

Table 57. Europe Overactive Bladder Drug Revenue by Country (2017-2022) & ($ Millions)

Table 58. Europe Overactive Bladder Drug Revenue Market Share by Country (2017-2022)

Table 59. Europe Overactive Bladder Drug Sales by Type (2017-2022) & (K Units)

Table 60. Europe Overactive Bladder Drug Sales Market Share by Type (2017-2022)

Table 61. Europe Overactive Bladder Drug Sales by Application (2017-2022) & (K Units)

Table 62. Europe Overactive Bladder Drug Sales Market Share by Application (2017-2022)

Table 63. Middle East & Africa Overactive Bladder Drug Sales by Country (2017-2022) & (K Units)

Table 64. Middle East & Africa Overactive Bladder Drug Sales Market Share by Country (2017-2022)

Table 65. Middle East & Africa Overactive Bladder Drug Revenue by Country (2017-2022) & ($ Millions)

Table 66. Middle East & Africa Overactive Bladder Drug Revenue Market Share by Country (2017-2022)

Table 67. Middle East & Africa Overactive Bladder Drug Sales by Type (2017-2022) & (K Units)

Table 68. Middle East & Africa Overactive Bladder Drug Sales Market Share by Type (2017-2022)

Table 69. Middle East & Africa Overactive Bladder Drug Sales by Application (2017-2022) & (K Units)

Table 70. Middle East & Africa Overactive Bladder Drug Sales Market Share by Application (2017-2022)

Table 71. Key Market Drivers & Growth Opportunities of Overactive Bladder Drug

Table 72. Key Market Challenges & Risks of Overactive Bladder Drug

Table 73. Key Industry Trends of Overactive Bladder Drug

Table 74. Overactive Bladder Drug Raw Material

Table 75. Key Suppliers of Raw Materials

Table 76. Overactive Bladder Drug Distributors List

Table 77. Overactive Bladder Drug Customer List

Table 78. Global Overactive Bladder Drug Sales Forecast by Region (2023-2028) & (K Units)

Table 79. Global Overactive Bladder Drug Sales Market Forecast by Region

Table 80. Global Overactive Bladder Drug Revenue Forecast by Region (2023-2028) & ($ millions)

Table 81. Global Overactive Bladder Drug Revenue Market Share Forecast by Region (2023-2028)

Table 82. Americas Overactive Bladder Drug Sales Forecast by Country (2023-2028) & (K Units)

Table 83. Americas Overactive Bladder Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 84. APAC Overactive Bladder Drug Sales Forecast by Region (2023-2028) & (K Units)

Table 85. APAC Overactive Bladder Drug Revenue Forecast by Region (2023-2028) & ($ millions)

Table 86. Europe Overactive Bladder Drug Sales Forecast by Country (2023-2028) & (K Units)

Table 87. Europe Overactive Bladder Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 88. Middle East & Africa Overactive Bladder Drug Sales Forecast by Country (2023-2028) & (K Units)

Table 89. Middle East & Africa Overactive Bladder Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 90. Global Overactive Bladder Drug Sales Forecast by Type (2023-2028) & (K Units)

Table 91. Global Overactive Bladder Drug Sales Market Share Forecast by Type (2023-2028)

Table 92. Global Overactive Bladder Drug Revenue Forecast by Type (2023-2028) & ($ Millions)

Table 93. Global Overactive Bladder Drug Revenue Market Share Forecast by Type (2023-2028)

Table 94. Global Overactive Bladder Drug Sales Forecast by Application (2023-2028) & (K Units)

Table 95. Global Overactive Bladder Drug Sales Market Share Forecast by Application (2023-2028)

Table 96. Global Overactive Bladder Drug Revenue Forecast by Application (2023-2028) & ($ Millions)

Table 97. Global Overactive Bladder Drug Revenue Market Share Forecast by Application (2023-2028)

Table 98. Astellas Pharma, Inc. (Japan) Basic Information, Overactive Bladder Drug Manufacturing Base, Sales Area and Its Competitors

Table 99. Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Product Offered

Table 100. Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)

Table 101. Astellas Pharma, Inc. (Japan) Main Business

Table 102. Astellas Pharma, Inc. (Japan) Latest Developments

Table 103. Pfizer, Inc. (US) Basic Information, Overactive Bladder Drug Manufacturing Base, Sales Area and Its Competitors

Table 104. Pfizer, Inc. (US) Overactive Bladder Drug Product Offered

Table 105. Pfizer, Inc. (US) Overactive Bladder Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)

Table 106. Pfizer, Inc. (US) Main Business

Table 107. Pfizer, Inc. (US) Latest Developments

Table 108. Teva Pharmaceutical Industries Limited (Israel) Basic Information, Overactive Bladder Drug Manufacturing Base, Sales Area and Its Competitors

Table 109. Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Product Offered

Table 110. Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)

Table 111. Teva Pharmaceutical Industries Limited (Israel) Main Business

Table 112. Teva Pharmaceutical Industries Limited (Israel) Latest Developments

Table 113. Allergan, Plc (Ireland) Basic Information, Overactive Bladder Drug Manufacturing Base, Sales Area and Its Competitors

Table 114. Allergan, Plc (Ireland) Overactive Bladder Drug Product Offered

Table 115. Allergan, Plc (Ireland) Overactive Bladder Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)

Table 116. Allergan, Plc (Ireland) Main Business

Table 117. Allergan, Plc (Ireland) Latest Developments

Table 118. Medtronic plc (Ireland) Basic Information, Overactive Bladder Drug Manufacturing Base, Sales Area and Its Competitors

Table 119. Medtronic plc (Ireland) Overactive Bladder Drug Product Offered

Table 120. Medtronic plc (Ireland) Overactive Bladder Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)

Table 121. Medtronic plc (Ireland) Main Business

Table 122. Medtronic plc (Ireland) Latest Developments

Table 123. Mylan N.V. (US) Basic Information, Overactive Bladder Drug Manufacturing Base, Sales Area and Its Competitors

Table 124. Mylan N.V. (US) Overactive Bladder Drug Product Offered

Table 125. Mylan N.V. (US) Overactive Bladder Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)

Table 126. Mylan N.V. (US) Main Business

Table 127. Mylan N.V. (US) Latest Developments

Table 128. Endo International plc (Ireland) Basic Information, Overactive Bladder Drug Manufacturing Base, Sales Area and Its Competitors

Table 129. Endo International plc (Ireland) Overactive Bladder Drug Product Offered

Table 130. Endo International plc (Ireland) Overactive Bladder Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)

Table 131. Endo International plc (Ireland) Main Business

Table 132. Endo International plc (Ireland) Latest Developments

Table 133. Hisamitsu Pharmaceutical Co., Inc. (Japan) Basic Information, Overactive Bladder Drug Manufacturing Base, Sales Area and Its Competitors

Table 134. Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Product Offered

Table 135. Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)

Table 136. Hisamitsu Pharmaceutical Co., Inc. (Japan) Main Business

Table 137. Hisamitsu Pharmaceutical Co., Inc. (Japan) Latest Developments

Table 138. Sanofi (France) Basic Information, Overactive Bladder Drug Manufacturing Base, Sales Area and Its Competitors

Table 139. Sanofi (France) Overactive Bladder Drug Product Offered

Table 140. Sanofi (France) Overactive Bladder Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)

Table 141. Sanofi (France) Main Business

Table 142. Sanofi (France) Latest Developments

Table 143. Apotex, Inc. (Canada) Basic Information, Overactive Bladder Drug Manufacturing Base, Sales Area and Its Competitors

Table 144. Apotex, Inc. (Canada) Overactive Bladder Drug Product Offered

Table 145. Apotex, Inc. (Canada) Overactive Bladder Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)

Table 146. Apotex, Inc. (Canada) Main Business

Table 147. Apotex, Inc. (Canada) Latest Developments

Table 148. Cogentix Medical, Inc. (US) Basic Information, Overactive Bladder Drug Manufacturing Base, Sales Area and Its Competitors

Table 149. Cogentix Medical, Inc. (US) Overactive Bladder Drug Product Offered

Table 150. Cogentix Medical, Inc. (US) Overactive Bladder Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)

Table 151. Cogentix Medical, Inc. (US) Main Business

Table 152. Cogentix Medical, Inc. (US) Latest Developments

Table 153. Aurobindo Pharma Limited (India) Basic Information, Overactive Bladder Drug Manufacturing Base, Sales Area and Its Competitors

Table 154. Aurobindo Pharma Limited (India) Overactive Bladder Drug Product Offered

Table 155. Aurobindo Pharma Limited (India) Overactive Bladder Drug Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)

Table 156. Aurobindo Pharma Limited (India) Main Business

Table 157. Aurobindo Pharma Limited (India) Latest Developments

List of Figures

Figure 1. Picture of Overactive Bladder Drug

Figure 2. Overactive Bladder Drug Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Overactive Bladder Drug Sales Growth Rate 2017-2028 (K Units)

Figure 7. Global Overactive Bladder Drug Revenue Growth Rate 2017-2028 ($ Millions)

Figure 8. Overactive Bladder Drug Sales by Region (2021 & 2028) & ($ millions)

Figure 9. Product Picture of Anticholinergics

Figure 10. Product Picture of Solifenacin

Figure 11. Product Picture of Oxybutynin

Figure 12. Product Picture of Darifenacin

Figure 13. Product Picture of Fesoterodine

Figure 14. Product Picture of Tolterodine

Figure 15. Product Picture of Trospium

Figure 16. Product Picture of Others

Figure 17. Global Overactive Bladder Drug Sales Market Share by Type in 2021

Figure 18. Global Overactive Bladder Drug Revenue Market Share by Type (2017-2022)

Figure 19. Overactive Bladder Drug Consumed in Idiopathic Bladder Overactivity

Figure 20. Global Overactive Bladder Drug Market: Idiopathic Bladder Overactivity (2017-2022) & (K Units)

Figure 21. Overactive Bladder Drug Consumed in Neurogenic Bladder Overactivity

Figure 22. Global Overactive Bladder Drug Market: Neurogenic Bladder Overactivity (2017-2022) & (K Units)

Figure 23. Global Overactive Bladder Drug Sales Market Share by Application (2017-2022)

Figure 24. Global Overactive Bladder Drug Revenue Market Share by Application in 2021

Figure 25. Overactive Bladder Drug Revenue Market by Company in 2021 ($ Million)

Figure 26. Global Overactive Bladder Drug Revenue Market Share by Company in 2021

Figure 27. Global Overactive Bladder Drug Sales Market Share by Geographic Region (2017-2022)

Figure 28. Global Overactive Bladder Drug Revenue Market Share by Geographic Region in 2021

Figure 29. Global Overactive Bladder Drug Sales Market Share by Region (2017-2022)

Figure 30. Global Overactive Bladder Drug Revenue Market Share by Country/Region in 2021

Figure 31. Americas Overactive Bladder Drug Sales 2017-2022 (K Units)

Figure 32. Americas Overactive Bladder Drug Revenue 2017-2022 ($ Millions)

Figure 33. APAC Overactive Bladder Drug Sales 2017-2022 (K Units)

Figure 34. APAC Overactive Bladder Drug Revenue 2017-2022 ($ Millions)

Figure 35. Europe Overactive Bladder Drug Sales 2017-2022 (K Units)

Figure 36. Europe Overactive Bladder Drug Revenue 2017-2022 ($ Millions)

Figure 37. Middle East & Africa Overactive Bladder Drug Sales 2017-2022 (K Units)

Figure 38. Middle East & Africa Overactive Bladder Drug Revenue 2017-2022 ($ Millions)

Figure 39. Americas Overactive Bladder Drug Sales Market Share by Country in 2021

Figure 40. Americas Overactive Bladder Drug Revenue Market Share by Country in 2021

Figure 41. United States Overactive Bladder Drug Revenue Growth 2017-2022 ($ Millions)

Figure 42. Canada Overactive Bladder Drug Revenue Growth 2017-2022 ($ Millions)

Figure 43. Mexico Overactive Bladder Drug Revenue Growth 2017-2022 ($ Millions)

Figure 44. Brazil Overactive Bladder Drug Revenue Growth 2017-2022 ($ Millions)

Figure 45. APAC Overactive Bladder Drug Sales Market Share by Region in 2021

Figure 46. APAC Overactive Bladder Drug Revenue Market Share by Regions in 2021

Figure 47. China Overactive Bladder Drug Revenue Growth 2017-2022 ($ Millions)

Figure 48. Japan Overactive Bladder Drug Revenue Growth 2017-2022 ($ Millions)

Figure 49. South Korea Overactive Bladder Drug Revenue Growth 2017-2022 ($ Millions)

Figure 50. Southeast Asia Overactive Bladder Drug Revenue Growth 2017-2022 ($ Millions)

Figure 51. India Overactive Bladder Drug Revenue Growth 2017-2022 ($ Millions)

Figure 52. Australia Overactive Bladder Drug Revenue Growth 2017-2022 ($ Millions)

Figure 53. Europe Overactive Bladder Drug Sales Market Share by Country in 2021

Figure 54. Europe Overactive Bladder Drug Revenue Market Share by Country in 2021

Figure 55. Germany Overactive Bladder Drug Revenue Growth 2017-2022 ($ Millions)

Figure 56. France Overactive Bladder Drug Revenue Growth 2017-2022 ($ Millions)

Figure 57. UK Overactive Bladder Drug Revenue Growth 2017-2022 ($ Millions)

Figure 58. Italy Overactive Bladder Drug Revenue Growth 2017-2022 ($ Millions)

Figure 59. Russia Overactive Bladder Drug Revenue Growth 2017-2022 ($ Millions)

Figure 60. Middle East & Africa Overactive Bladder Drug Sales Market Share by Country in 2021

Figure 61. Middle East & Africa Overactive Bladder Drug Revenue Market Share by Country in 2021

Figure 62. Egypt Overactive Bladder Drug Revenue Growth 2017-2022 ($ Millions)

Figure 63. South Africa Overactive Bladder Drug Revenue Growth 2017-2022 ($ Millions)

Figure 64. Israel Overactive Bladder Drug Revenue Growth 2017-2022 ($ Millions)

Figure 65. Turkey Overactive Bladder Drug Revenue Growth 2017-2022 ($ Millions)

Figure 66. GCC Country Overactive Bladder Drug Revenue Growth 2017-2022 ($ Millions)

Figure 67. Manufacturing Cost Structure Analysis of Overactive Bladder Drug in 2021

Figure 68. Manufacturing Process Analysis of Overactive Bladder Drug

Figure 69. Industry Chain Structure of Overactive Bladder Drug

Figure 70. Channels of Distribution

Figure 71. Distributors Profiles